Shanghai wisechem will present cutting-edge research results at the 2015 annual meeting of the American Association for cancer research

As a long-term partner of global pharmaceutical R & D enterprises, chempartner has always adhered to the concept of scientific research as the driving force and technology as the basis Shanghai wisechem will present its latest research progress on the basic research and clinical important topic of tumor drug resistance at the annual meeting of the American Association of cancer (2015 AACR) held in Philadelphia from April 18 to 22 It is reported that the annual meeting of the American Society of oncology and oncology has 19000 participants Intelligent chemical researchers have been committed to the development of clinical related scientific research, including human tumor model (PDX) Different from most of the methods of cell culture in vitro to induce drug resistance, wise chemical uses long-term drug administration in vivo to induce PDX model drug resistance to simulate the clinical occurrence of drug resistance This kind of drug resistance based on the interaction of tumor host is more close to the clinical situation Through this study, wise chemical has established a group of hepatoma cell lines sensitive to and resistant to sorafenib in vivo from tumor samples from the same patient source Through the in-depth analysis of these two cell lines and their parent tumor models, we try to reveal the mechanism of drug resistance In order to make a more comprehensive and objective analysis and avoid the methodological deviation, wise chemical also uses multi-component analysis to carry out gene expression microarray analysis, RT-qPCR verification, full exome sequencing, transcriptome sequencing and metabolome analysis on the tumor cell line, and the company's bioinformatics team conducts data analysis and integration Some of their findings will be presented at the AACR annual meeting next week Since 2006, smart chemical oncology has been providing quality services to more than 150 pharmaceutical companies and biotechnology companies around the world, with the largest cell testing platform (more than 700 cell lines) and the most comprehensive epigenetic enzyme analysis platform (130 At the same time, it has rich research experience in tumor metabolism, epigenetics and tumor immunology In recent years, through its sister company, clinical explorer, wise chemical oncology department has established extensive cooperation with the hospital to expand its research field of translational medicine PDX platform (patient derived xenograft) is one of the fruitful results of these cooperation Based on its in-depth research expertise in preclinical and biomarker fields, pioneer medicine is committed to transforming basic research results into powerful means of clinical diagnosis and treatment, and truly "from laboratory to hospital bed" (Bio Valley bio Com) for more information about smart chemistry and sunflower, please click about smart chemistry and sunflower group, as an important part of sunflower pharmaceutical R & D service group, is a research institution providing high-quality and efficient services for pharmaceutical and biotechnology industries The company provides high-quality comprehensive services for global pharmaceutical and biotechnology companies, including research and development of biological agents, chemical research and development, preclinical research, pharmaceutical development, production services of small molecule and antibody drugs, etc Shanghua group insists on developing and providing advanced scientific and technological methods to assist global partners in developing new therapeutic methods Based on this mission, Shanghua group has set up Shanghai Pharma, which focuses on new technology development, in addition to the R & D service platform of Shanghai chempartner Technologies, Shanghua Technology), as well as Shanghai Pharma investments, which is committed to early new thinking investment, provide innovative foundation for future drug therapy Shanghua group hopes to establish a large industrial ecosystem through all-round and multi-channel services, so as to promote the close interaction between hospitals, academic centers, enterprises and research institutes, and ultimately achieve common development The group is actively investing, licensing and partnering to better serve the healthcare industry